AbbVie (NYSE:ABBV)
AbbVie is a drug company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women’s health.
Get Real Time Here
| Open- | Close246.200 |
| Vol / Avg.4.839K / 6.823M | Mkt Cap438.299B |
| Day Range- - - | 52 Wk Range190.750 - 267.470 |
Immix Biopharma (NASDAQ:IMMX)
Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Its product candidate drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME.
Get Real Time Here
| Open- | Close9.540 |
| Vol / Avg.2.981K / 1.767M | Mkt Cap677.016M |
| Day Range- - - | 52 Wk Range1.940 - 12.140 |
Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson is the world’s largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
Get Real Time Here
| Open- | Close- |
| Vol / Avg.10.252K / 8.227M | Mkt Cap626.453B |
| Day Range- - - | 52 Wk Range169.650 - 274.900 |
Pfizer (NYSE:PFE)
Founded in 1849 and headquartered in New York, New York, Pfizer Inc. discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products worldwide, offering medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, women’s health, infectious diseases with unmet medical needs, COVID-19 prevention and treatment along with potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. Pfizer also provides medicines and vaccines in various therapeutic areas, amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, sterile injectable and anti-infective medicines and biologics, small molecules, immunotherapies and biosimilars. Pfizer also maintains collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US Inc., Myovant Sciences Ltd., Merck KGaA, Valneva SE, BioNTech SE and Arvinas, Inc.
Get Real Time Here
| Open- | Close25.810 |
| Vol / Avg.272.408K / 42.016M | Mkt Cap147.422B |
| Day Range- - - | 52 Wk Range23.580 - 28.745 |
uniQure (NASDAQ:QURE)
uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington’s disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Get Real Time Here
| Open- | Close44.240 |
| Vol / Avg.311.000 / 2.135M | Mkt Cap3.073B |
| Day Range- - - | 52 Wk Range8.730 - 71.500 |
Kiora Pharmaceuticals (NASDAQ:KPRX)
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The products pipeline of the company includes KIO-101, KIO-201, KIO-301, and KIO-102.
Get Real Time Here
| Open- | Close2.540 |
| Vol / Avg.66.000 / 32.096K | Mkt Cap11.168M |
| Day Range- - - | 52 Wk Range1.765 - 3.010 |
()
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Quoin Pharmaceuticals (NASDAQ:QNRX)
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Get Real Time Here
| Open- | Close4.370 |
| Vol / Avg.1.000 / 234.298K | Mkt Cap8.713M |
| Day Range- - - | 52 Wk Range3.250 - 41.800 |
Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a vaccine and boosters that can eradicate COVID-19.
Tilt your stock portfolio toward biotech companies now and you could stand to make substantial profits in the near future.
You can also find cost-effective stocks under $20 to trade daily on the stock exchange.
Stock Movers
Gainers
| Ticker | Company | Close | ±% | Avg. Vol | Buy Stock | |
|---|---|---|---|---|---|---|
No Results |
Loser
| Ticker | Company | Close | ±% | Avg. Vol | Buy Stock | |
|---|---|---|---|---|---|---|
No Results |
Overview: Biotech Stocks
Biotech companies are a subsector of healthcare stocks that primarily focus on developing new drugs and treatments for medical conditions, diseases and viruses. The stock value and growth potential of a biotech firm depend on the type of diseases it treats. This might also include the research that the firm does as it supports other companies, diseases or treatments.
For instance, a biotech firm working on breast cancer treatments, which has nearly 300,000 new cases in the U.S. each year, might be more valuable than a company that is developing drugs for Ogilvie's Syndrome, a rare disease that only affects 1%–3% of the population.
Every new drug developed by biotech firms has to be submitted to the Food and Drug Association (FDA) for approval. Medical companies spend years developing a new drug but may fail to get it approved by the FDA. Some of these drugs will never hit the shelf of pharmaceuticals even after countless clinical trials. On the other hand, if a biotech company gets a new drug sanctioned by the FDA and the demand is high, the stock value can double or even triple overnight.
Best Online Brokers for Biotech Stock
An online broker can help you trade biotech stocks with speed and precision.
You can gain access to professional-level trading tools such as stock screens by opening an account on these platforms. Online brokers let you apply custom filters such as setting a price range to narrow down stocks under $10 within minutes.
Explore these online brokers to get started today.
- Good Fit For:Active and Global TradersVIEW PROS & CONS:Securely through Interactive Brokers’ website
- Good Fit For:Leveraged TradingVIEW PROS & CONS:securely through Plus500 Yield's website
- Good Fit For:Commission-Free Mobile TradingVIEW PROS & CONS:securely through Robinhood's website
- Good Fit For:Active Short SellersVIEW PROS & CONS:securely through TradeZero [SPONSORED]'s website
Features to Look for in Biotech Stock
- Earnings per share: You can determine the profitability of a company by its earnings per share (EPS). It is calculated by dividing the net income of the company by the total number of its outstanding shares.
- Price-earnings ratio: The price-earnings ratio (P/E ratio) is calculated by dividing the current stock price by its EPS. Based on the P/E ratio, you can assess if a stock is undervalued or overvalued. The lower the P/E ratio of the stock, the better an investment it is. Generally, penny stocks under $5 have the lowest P/E ratios.
- Medical innovation: Biotech firms can spend years conducting clinical trials to test a new drug. Keep a constant watch on any news regarding medical breakthroughs and FDA approvals to make the most of your trade.
- Relevancy: Apart from medical innovation, you need to invest in stocks that are relevant—and continue to remain relevant. Research specifically what these companies do, drugs they’re working on, therapies that they have created and how those ideas remain in the headlines, even if the company is rather old.
Be Patient for Better Profits
Advanced medical technology has led to longer and more fulfilling lives. An investment in biotech stocks involves longer buy-and-hold periods, but if you are patient with your trades, you can strike gold when you least expect it. Remember, the biotech industry can shift very quickly, like during the COVID-19 pandemic. Be patient, do the research and don’t be afraid to exit positions that might not work well for you. Every industry shifts at different times, and that’s why patience is so critical for investors.
Frequently Asked Questions
What is biotech?
Biotech is the area of biology that uses living processes, organisms and systems to manufacture products or technologies. Usually these products are intended to improve human life.
Is biotech worth investing in?
Biotech can be a great long-term investment.
What small biotech company did Jeff Bezos invest in?
Jeff Bezos invested in Altos Labs, which is a startup that concentrates on extending the human life.
Continue reading:
Facts Only
* AbbVie focuses on immunology and oncology; Humira provides nearly half of its profits.
* AbbVie spun off from Abbott in early 2013 and acquired Allergan.
* Immix Biopharma is a clinical-stage company developing Tissue-Specific Therapeutics for oncology and inflammation.
* Johnson & Johnson operates pharmaceutical, medical devices and diagnostics, and consumer divisions.
* Pfizer is headquartered in New York and produces medicines and vaccines, including Comirnaty and Paxlovid.
* Pfizer maintains collaboration agreements with companies including BioNTech SE and Bristol-Myers Squibb.
* uniQure develops gene therapies for hemophilia, Huntington’s disease, and cardiovascular diseases.
* Kiora Pharmaceuticals develops products for treating eye diseases, including KIO-101, KIO-201, KIO-301, and KIO-102.
* Inozyme Pharma develops therapeutics for ENPP1 and ABCC6 deficiencies using product candidate INZ-701.
* Quoin Pharmaceuticals targets rare diseases including Netherton Syndrome and Epidermolysis Bullosa.
* The FDA must approve new drugs before they are marketed.
* Jeff Bezos invested in Altos Labs, a startup focused on extending human life.
Executive Summary
The biotechnology sector consists of diverse entities ranging from global healthcare giants like Johnson & Johnson and Pfizer to specialized, clinical-stage firms such as Kiora Pharmaceuticals and Quoin Pharmaceuticals. These companies focus on a wide array of therapeutic areas, including oncology, immunology, gene therapy, and the treatment of rare orphan diseases. While larger firms maintain diversified portfolios across pharmaceuticals and consumer health, smaller biotech firms often rely on the success of specific product candidates undergoing clinical trials.
Investment in this sector is characterized by high volatility and long-term horizons. The financial viability of biotech stocks is heavily contingent upon FDA approval processes; a single sanction can significantly increase a company's valuation, while failure in clinical trials can prevent a drug from ever reaching the market. Current market interest is partially driven by the global recovery from the pandemic and the ongoing development of vaccines and boosters. Investors typically evaluate these opportunities using metrics such as earnings per share (EPS) and price-earnings (P/E) ratios to determine valuation.
Full Take
The strongest version of this narrative is that biotechnology offers a high-reward investment frontier where medical innovation directly translates into financial gain, provided the investor has the patience to withstand the binary nature of FDA approvals.
However, the structure of the presentation reveals a transition from neutral corporate descriptions to active financial solicitation. By framing the sector as being "in the eye of the storm" and suggesting readers "tilt" their portfolios to "strike gold," the narrative shifts from information to persuasion. The inclusion of specific broker recommendations and the promotion of "cost-effective stocks under $20" suggests a goal of driving retail trading activity rather than providing a comprehensive medical or financial analysis. This creates a decision frame where the complexity of drug development is reduced to a simple gamble on FDA outcomes.
Patterns detected: ARC-0024 Ambiguity, ARC-0043 Motte-and-Bailey
The underlying paradigm is the "financialization of health," where life-saving innovations are presented primarily as vehicles for "substantial profits." The unstated assumption is that retail investors possess the specialized knowledge required to distinguish between viable clinical-stage candidates and those destined for failure.
If this were a coordinated influence campaign, the playbook would involve listing several legitimate, high-cap companies to build credibility, then pivoting to low-cap "penny stocks" to drive liquidity toward specific volatile assets, all while using the urgency of a global health crisis (COVID-19) as a catalyst. The content aligns structurally with this pattern by blending a corporate directory with direct calls to action and broker links.
Bridge Questions:
1. How does the promotion of "stocks under $20" align with the stated advice to research long-term medical innovation?
2. What risks are omitted when comparing the value of a company treating common cancer versus one treating a rare syndrome?
3. Who benefits more from the "tilting" of portfolios: the medical patients or the trading platforms listed?